A. Lopez-beltran, M. Scarpelli, R. Montironi, and Z. Kirkali, 2004 WHO Classification of the Renal Tumors of the Adults, European Urology, vol.49, issue.5, pp.798-805, 2006.
DOI : 10.1016/j.eururo.2005.11.035

Z. Kirkali, F. Algaba, M. Scarpelli, I. Trias, F. Selvaggi et al., What Does the Urologist Expect from the Pathologist (and What Can the Pathologists Give) in Reporting on Adult Kidney Tumour Specimens?, European Urology, vol.51, issue.5, pp.1194-201, 2007.
DOI : 10.1016/j.eururo.2006.11.024

O. Iliopoulos, A. Kibel, S. Gray, W. Kaelin, and J. , Tumour suppression by the human von Hippel-Lindau gene product, Nature Medicine, vol.162, issue.8, pp.822-828, 1995.
DOI : 10.1038/nm0895-822

K. Foster, A. Prowse, A. Van-den-berg, S. Fleming, M. Hulsbeek et al., Somatic mutations of the von Hippel ??? Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma, Human Molecular Genetics, vol.3, issue.12, pp.2169-73, 1994.
DOI : 10.1093/hmg/3.12.2169

K. Kondo, W. Kaelin, and J. , The von Hippel???Lindau Tumor Suppressor Gene, Experimental Cell Research, vol.264, issue.1, pp.117-142, 2001.
DOI : 10.1006/excr.2000.5139

N. Ferrara, H. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nature Medicine, vol.9, issue.6, pp.669-76, 2003.
DOI : 10.1038/nm0603-669

R. Jain, Molecular regulation of vessel maturation, Nature Medicine, vol.9, issue.6, pp.685-93, 2003.
DOI : 10.1038/nm0603-685

I. Vivanco and C. Sawyers, The phosphatidylinositol 3-Kinase???AKT pathway in human cancer, Nature Reviews Cancer, vol.2, issue.7, pp.489-501, 2002.
DOI : 10.1038/nrc839

D. Sabatini, mTOR and cancer: insights into a complex relationship, Nature Reviews Cancer, vol.10, issue.9, pp.729-763, 2006.
DOI : 10.1038/nrc1974

J. Everitt, C. Walker, T. Goldsworthy, and D. Wolf, Altered expression of transforming growth factor-??: An early event in renal cell carcinoma development, Molecular Carcinogenesis, vol.35, issue.3, pp.213-222, 1997.
DOI : 10.1002/(SICI)1098-2744(199707)19:3<213::AID-MC9>3.0.CO;2-E

L. Schmidt, F. Duh, F. Chen, T. Kishida, G. Glenn et al., Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas, Nature Genetics, vol.4, issue.1, pp.68-73, 1997.
DOI : 10.1038/ng1295-402

C. Boccaccio and P. Comoglio, Invasive growth: a MET-driven genetic programme for cancer and stem cells, Nature Reviews Cancer, vol.16, issue.8, pp.637-682, 2006.
DOI : 10.1038/nrc1912

I. Tomlinson, N. Alam, A. Rowan, E. Barclay, E. Jaeger et al., Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer, Nature Genetics, vol.30, issue.4, pp.406-416, 2002.
DOI : 10.1038/ng849

B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard et al., Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007.
DOI : 10.1056/NEJMoa060655

A. Rodriguez and M. Fishman, Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines, Expert Opinion on Pharmacotherapy, vol.24, issue.17, pp.2979-90, 2007.
DOI : 10.1200/JCO.2005.10.017

G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin et al., Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, pp.2271-81, 2007.
DOI : 10.1056/NEJMoa066838

R. Motzer, B. Escudier, S. Oudard, T. Hutson, C. Porta et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-56, 2008.
DOI : 10.1016/S0140-6736(08)61039-9

B. Olenyuk, G. Zhang, J. Klco, N. Nickols, W. Kaelin et al., Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist, Proceedings of the National Academy of Sciences, vol.101, issue.48, pp.16768-73, 2004.
DOI : 10.1073/pnas.0407617101

G. Bergers and D. Hanahan, Modes of resistance to anti-angiogenic therapy, Nature Reviews Cancer, vol.25, issue.8, pp.592-603, 2008.
DOI : 10.1038/nrc2442

J. Sosman, I. Puzanov, and M. Atkins, Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer, Clinical Cancer Research, vol.13, issue.2, pp.764-69, 2007.
DOI : 10.1158/1078-0432.CCR-06-1975

A. Parker, J. Cheville, C. Lohse, T. Igel, B. Leibovich et al., Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma, Urology, vol.65, issue.6, pp.1090-1095, 2005.
DOI : 10.1016/j.urology.2004.12.040

T. Choueiri, S. Vaziri, E. Jaeger, P. Elson, L. Wood et al., von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma, The Journal of Urology, vol.180, issue.3, pp.860-865, 2008.
DOI : 10.1016/j.juro.2008.05.015

T. Klatte, D. Seligson, S. Riggs, J. Leppert, M. Berkman et al., Hypoxia-Inducible Factor 1?? in Clear Cell Renal Cell Carcinoma, Clinical Cancer Research, vol.13, issue.24, pp.7388-93, 2007.
DOI : 10.1158/1078-0432.CCR-07-0411

M. Bui, D. Seligson, K. Han, A. Pantuck, F. Dorey et al., Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy, Clin Cancer Res, vol.9, pp.802-813, 2003.

P. Patel, R. Chadalavada, and N. Ishil, Hypoxia-inducible factor (HIF) 1?? and 2?? levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC), Journal of Clinical Oncology, vol.26, issue.15_suppl, p.5008, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.5008

N. Rioux-leclercq, P. Fergelot, S. Zerrouki, E. Leray, F. Jouan et al., Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases, Human Pathology, vol.38, issue.10, pp.1489-95, 2007.
DOI : 10.1016/j.humpath.2007.02.014

A. Pantuck, D. Seligson, T. Klatte, H. Yu, J. Leppert et al., Prognostic relevance of the mTOR pathway in renal cell carcinoma, Cancer, vol.9, issue.11, pp.2257-67, 2007.
DOI : 10.1002/cncr.22677

D. Cho, S. Signoretti, S. Dabora, M. Regan, A. Seeley et al., Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma, Clinical Genitourinary Cancer, vol.5, issue.6, pp.379-85, 2007.
DOI : 10.3816/CGC.2007.n.020